2126 JW (Cayman) Therapeutics Co. Ltd. HKEX · China

JW (Cayman) Therapeutics Co. (2126) news

JW (Cayman) Therapeutics Co. Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2126, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest JW (Cayman) Therapeutics Co. news

We have not published a story on JW (Cayman) Therapeutics Co. yet. When there is news, it will appear here.

Questions about JW (Cayman) Therapeutics Co.

What is the ticker symbol of JW (Cayman) Therapeutics Co.?

JW (Cayman) Therapeutics Co. Ltd. trades under the ticker 2126 on HKEX.

Where is JW (Cayman) Therapeutics Co. listed?

JW (Cayman) Therapeutics Co. Ltd. is listed on HKEX.

Which country or territory is JW (Cayman) Therapeutics Co. listed under?

Our directory records JW (Cayman) Therapeutics Co. Ltd. under China.

What does JW (Cayman) Therapeutics Co. do?

Our directory classifies JW (Cayman) Therapeutics Co. Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of JW (Cayman) Therapeutics Co.?

The ISIN recorded for JW (Cayman) Therapeutics Co. Ltd. is KYG5210T1040.

Does aibio.space cover JW (Cayman) Therapeutics Co.?

aibio.space lists JW (Cayman) Therapeutics Co. Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to JW (Cayman) Therapeutics Co.?

Companies in our directory listed in the same country and business area as JW (Cayman) Therapeutics Co.: Ascletis Pharma, Beijing Luzhu Biotechnology Co., Sunshine Lake Pharma Co., AIM Vaccine Co., IMPACT Therapeutics, Brii Biosciences.

Investor discussion: JW (Cayman) Therapeutics Co.

Members talk about JW (Cayman) Therapeutics Co. (2126). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at JW (Cayman) Therapeutics Co., newest first. Each line links the filing it comes from.

May 26, 2026Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS AND RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING. Source
Oct 30, 2025Mergers
Transaction under the Listing Rules: MAJOR TRANSACTION IN RELATION TO AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT. Source
May 8, 2025Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS AND RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of JW (Cayman) Therapeutics Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Aug 27, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jun 26, 2026HKEXnews
(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026; (2) RETIREMENT OF DIRECTORS, CHANGE OF CHAIRMAN; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEE
May 26, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
May 26, 2026HKEXnews
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS AND RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING
May 19, 2026HKEXnews
GRANT OF SHARE OPTIONS
Apr 20, 2026HKEXnews
GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARE UNITS
Mar 26, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Dec 22, 2025HKEXnews
CONTINUING CONNECTED TRANSACTION IN RELATION TO EXTENSION OF TERM OF VECTOR SUPPLY AGREEMENT
Dec 11, 2025HKEXnews
(1) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR; (2) APPOINTMENT OF CHAIRMAN OF THE BOARD; (3) RESIGNATION OF CHIEF EXECUTIVE OFFICER, CHAIRMAN AND EXECUTIVE DIRECTOR; (4) CANCELLATION OF GRANT OF SHARE OPTIONS; (5) CHANGE IN COMPOSITION OF BOARD COMMITTEES AND (6) CHANGE OF AUTHORIZED REPRESENTATIVE
Dec 8, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - PRESENTATION OF JWCAR201 IIT STUDY DATA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
Oct 30, 2025HKEXnews
MAJOR TRANSACTION IN RELATION TO AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT
Oct 21, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - DATA SUBMITTED FROM PHASE I STUDY OF RELMA-CEL IN CHINESE ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TO NMPA
Oct 9, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE - NATIONAL MEDICAL PRODUCTS ADMINISTRATION OFFICIALLY ACCEPTED THE POST-MARKETING SUPPLEMENTAL APPLICATION FOR CARTEYVA, WHICH USES AN IN-HOUSE PRODUCED LENTIVIRAL VECTOR
Sep 30, 2025HKEXnews
DELAY IN DESPATCH OF CIRCULAR
Aug 27, 2025HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING
Jun 26, 2025HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025
Jun 3, 2025HKEXnews
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 3, 2025
May 28, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA AS SECOND-LINE TREATMENT IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
May 15, 2025HKEXnews
Documents on Display
May 15, 2025HKEXnews
NOTICE OF EXTRAORDINARY GENERAL MEETING

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2126 on TradingView.

Listing details

Company: JW (Cayman) Therapeutics Co. Ltd.
Ticker: 2126
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: KYG5210T1040
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction